Bioasis Technologies Inc. (CVE:BTI – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$0.01 and traded as low as C$0.01. Bioasis Technologies shares last traded at C$0.01, with a volume of 5,250 shares traded.
Bioasis Technologies Stock Down 50.0%
The firm’s 50 day moving average price is C$0.01 and its two-hundred day moving average price is C$0.01. The firm has a market capitalization of C$397,050.00, a PE ratio of -0.12 and a beta of 0.45. The company has a quick ratio of 0.17, a current ratio of 0.11 and a debt-to-equity ratio of 27.88.
About Bioasis Technologies
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007).
Featured Articles
- Five stocks we like better than Bioasis Technologies
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
